menu
    • menu
    [{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lanraplenib","moa":"Syk","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Not Applicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Not Applicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lanraplenib","moa":"Syk","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Not Applicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lanraplenib","moa":"Syk","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Blood and Marrow Transplant Clinical Trials Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Blood and Marrow Transplant Clinical Trials Network","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Blood and Marrow Transplant Clinical Trials Network"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Iadademstat","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kotobuki Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Kotobuki Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Kotobuki Pharmaceutical"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kotobuki Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Kotobuki Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Kotobuki Pharmaceutical"},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ERAS-007","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ European Commission","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Genomics \/ European Commission"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ AstraZeneca"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Gilteritinib Fumarate

    Menu

    Gilteritinib Fumarate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kura Oncology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Kura Oncology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ziftomenib,Gilteritinib Fumarate,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kura Doses First Patient in KOMET-008 Trial of Ziftomenib with Standards of Care in AML

                            Details : KO-539 (ziftomenib) is a potent and selective a menin-MLL(KMT2A) inhibitor, which is being evaluated in phase 1 clinical trials in patients with NPM1-mutant & KMT2A-rearranged acute myeloid leukemia.

                            Brand Name : KO-539

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 26, 2024

                            Lead Product(s) : Ziftomenib,Gilteritinib Fumarate,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Astellas Pharma

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gilteritinib Fumarate,Venetoclax,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinical Trial Evaluates Triple-Drug Regimen for FLT3-Mutated AML

                            Details : Xospata (gilteritinib) is a receptor tyrosine kinase inhibitor being evaluated in combination with venetoclax and azacitidine for relapsed/refractory AML with an FLT3 mutation.

                            Brand Name : Xospata

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 30, 2024

                            Lead Product(s) : Gilteritinib Fumarate,Venetoclax,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kura Oncology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Kura Oncology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ziftomenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : BofA Securities

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-funded Warrants

                            Details : The net proceeds will be used for the development of KO-539 (ziftomenib), a potent and selective inhibitor, being developed in combination with Xospata (gilteritinib), an inhibitor of FLT3, for the treatment of NPM1-mutated acute myeloid leukemia.

                            Brand Name : KO-539

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 14, 2023

                            Lead Product(s) : Ziftomenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : BofA Securities

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kura Oncology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Kura Oncology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ziftomenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : BofA Securities

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-funded Warrants

                            Details : The net proceeds will be used for the development of KO-539 (ziftomenib), a potent and selective inhibitor, being developed in combination with Xospata (gilteritinib), an inhibitor of FLT3, for the treatment of NPM1-mutated acute myeloid leukemia.

                            Brand Name : KO-539

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 13, 2023

                            Lead Product(s) : Ziftomenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : BofA Securities

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oryzon Genomics

                            Spain arrow
                            Antibody Engineering
                            Not Confirmed

                            Oryzon Genomics

                            Spain arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iadademstat,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-muta...

                            Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1 with powerful differentiating effect in hematologic cancer. It is being investigated in with gilteritinib for relapsed/refractory AML harboring a FMS-like tyrosine kinas...

                            Brand Name : ORY-1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 15, 2023

                            Lead Product(s) : Iadademstat,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Astellas Pharma

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Blood and Marrow Transplant Clinical Trials Network

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib

                            Details : Xospata (gilteritinib) is a FLT3 inhibitor with demonstrated activity against FLT3-ITD, a common driver mutation that presents with a high disease burden and poor prognosis, and FLT3-tyrosine kinase domain mutations.

                            Brand Name : Xospata

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 09, 2023

                            Lead Product(s) : Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Blood and Marrow Transplant Clinical Trials Network

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kronos Bio

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanraplenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

                            Details : Lanraplenib (Lanra) has demonstrated favorable pharmacokinetic (PK), pharmacodynamic (PD) and safety in more than 250 trial participants, including healthy volunteers and patients with autoimmune diseases.

                            Brand Name : Lanra

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 08, 2022

                            Lead Product(s) : Lanraplenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kronos Bio

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanraplenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilte...

                            Details : Lanra (lanraplenib) is the company’s next-generation spleen tyrosine kinase (SYK) inhibitor. In addition to lanraplenib, Kronos Bio is also evaluating its lead investigational SYK inhibitor, entospletinib, in the Phase 3 patients with NPM1-mutated AML.

                            Brand Name : Lanra

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 22, 2022

                            Lead Product(s) : Lanraplenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Oryzon Genomics

                            Spain arrow
                            Antibody Engineering
                            Not Confirmed

                            Oryzon Genomics

                            Spain arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iadademstat,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : European Commission

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ORYZON Awarded EU Seal of Excellence and Public Financing of 2 M USD to Develop Ladademstat in Acute Myeloid L...

                            Details : The net proceeds will be used to evaluate efficacy and optimal dose of ORY-1001 (iadademstat), a novel, highly potent, and selective inhibitor of LSD1, plus Xospata (gilteritinib), an inhibitor of FLT3, in patients with relapsed/refractory AML with FLT3 ...

                            Brand Name : ORY-1001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 07, 2022

                            Lead Product(s) : Iadademstat,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : European Commission

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Erasca

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Erasca

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERAS-007,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-in-Class Progr...

                            Details : ERAS-007 is a highly potent and selective small molecule ERK1/2 inhibitor. It is being evaluated in phase 1/2 clinical trials in combination with gilteritinib for the treatment of acute myeloid leukemia.

                            Brand Name : ERAS-007

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 12, 2022

                            Lead Product(s) : ERAS-007,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth